Virpax receives Nasdaq deficiency notice; CEO and CFO resign citing policy disagreements

Virpax Pharmaceuticals, Inc.

Nasdaq notified Virpax that its bid price was below $1.00 for 30 consecutive days; compliance deadline April 2, 2025.
CEO Gerald Bruce and CFO Vinay Shah resigned Oct 5 effective immediately, citing disagreements with Board's execution of policies.
Board appointed director Jatinder Dhaliwal as CEO effective Oct 6; Katharyn Field joins audit committee replacing Dhaliwal.
Company may consider a reverse stock split to regain compliance, but no assurance of success.

item 3.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jatinder Dhaliwal

Chief Executive Officer

Virpax Pharmaceuticals, Inc.

Effective: 2024-10-06
Filed: October 7, 2024, 7:59 PM ET

On October 6, 2024, the Board appointed Jatinder Dhaliwal, a member of the Board, to serve as Chief Executive Officer of the Company, effective immediately.

Departed

Vinay Shah

Chief Financial Officer

Virpax Pharmaceuticals, Inc.

Effective: 2024-10-05
Filed: October 7, 2024, 7:59 PM ET

On October 5, 2024, Gerald Bruce, as Chief Executive Officer and member of the Board of Directors (the “Board”), and Vinay Shah, as Chief Financial Officer, notified the Company of their intention to resign for their respective positions, effective immediately.

Departed

Gerald Bruce

Chief Executive Officer

Virpax Pharmaceuticals, Inc.

Effective: 2024-10-05
Successor: Jatinder Dhaliwal
Filed: October 7, 2024, 7:59 PM ET

On October 5, 2024, Gerald Bruce, as Chief Executive Officer and member of the Board of Directors (the “Board”), and Vinay Shah, as Chief Financial Officer, notified the Company of their intention to resign for their respective positions, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jatinder Dhaliwal was appointed as Chief Executive Officer at Virpax Pharmaceuticals, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On October 6, 2024, the Board appointed Jatinder Dhaliwal, a member of the Board, to serve as Chief Executive Officer of the Company, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Vinay Shah resigned as Chief Financial Officer at Virpax Pharmaceuticals, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On October 5, 2024, Gerald Bruce, as Chief Executive Officer and member of the Board of Directors (the “Board”), and Vinay Shah, as Chief Financial Officer, notified the Company of their intention to resign for their respective positions, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gerald Bruce resigned as Chief Executive Officer at Virpax Pharmaceuticals, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

On October 5, 2024, Gerald Bruce, as Chief Executive Officer and member of the Board of Directors (the “Board”), and Vinay Shah, as Chief Financial Officer, notified the Company of their intention to resign for their respective positions, effective immediately.

View on SEC.gov

Source: SEC EDGAR

accession 0001731122-24-001548

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.